The global transient protein expression market is driven by demand for rapid, scalable production of recombinant proteins, antibodies, and viral vectors without the need to create stable cell lines. Mammalian systems such as HEK293 and CHO cells dominate, alongside insect, bacterial, and cell-free platforms. Biopharmaceutical R&D, vaccine development, and gene therapy programs are key end...